ArticleEJHaem2025

Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial.

Arjun Pandey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.